Adalimumab Therapy Is Associated With Reduced Risk of Hospitalization in Patients With Ulcerative Colitis

Overview of attention for article published in Gastroenterology, September 2013

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (92nd percentile)
High Attention Score compared to outputs of the same age and source (80th percentile)

Mentioned by

policy: 2 policy sources
twitter: 6 X users

guideline: 3 clinical guideline sources

Readers on

mendeley: 115 Mendeley

So far, Altmetric has seen 2 policy documents that reference this research output.

Biologics versus Immunomodulators for the Treatment of Ulcerative Colitis: A Review of Comparative Clinical Effectiveness and Cost-Effectiveness

Cited by Canadian Agency for Drugs and Technologies in Health (CADTH) on 17 Apr 2019

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

Tofacitinib for moderately to severely active ulcerative colitis : Committee papers

Cited by National Institute for Health and Care Excellence (NICE) on 21 Sep 2018

The National Institute for Health and Care Excellence (NICE) in the UK provides national guidance and advice to improve health and social care.

This page shows the most recent policy documents that mention this research output. Click here to find out how to access more activity.